Recent developments

at Tullis and our portfolio companies

News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

July

21

Exagen to Announce Second Quarter Financial Results on August 4, 2026

CARLSBAD, Calif., July 21, 2026 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune...

10

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results

Record full-year total revenue and AVISE® CTD average selling price New biomarkers and sales force...

11

Exagen Inc. to Participate in Fourth Quarter Investor Conferences

CARLSBAD, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing,...

1

Exagen Appoints Jeffrey G. Black as New Chief Financial Officer

CARLSBAD, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing...

7

Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance

CARLSBAD, Calif., Jan. 07, 2024 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing...

13

Exagen Inc. Reports Strong Third Quarter 2023 Results

SAN DIEGO, California, Nov. 13, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune...

7

Exagen Inc. Reports Strong Second Quarter 2023 Results

SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing...

24

Exagen Inc. Appoints Paul Kim to Board of Directors

SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing...

23

Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors

SAN DIEGO, Jan. 23, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions,...

1

Exagen Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients

SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing...

Recent developments

News

July

21

Exagen to Announce Second Quarter Financial Results on August 4, 2026

March

10

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results

November

11

Exagen Inc. to Participate in Fourth Quarter Investor Conferences

August

1

Exagen Appoints Jeffrey G. Black as New Chief Financial Officer

January

7

Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance

November

13

Exagen Inc. Reports Strong Third Quarter 2023 Results

August

7

Exagen Inc. Reports Strong Second Quarter 2023 Results

July

24

Exagen Inc. Appoints Paul Kim to Board of Directors

January

23

Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors

September

1

Exagen Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients